ClinicalTrials.gg
RecruitingNCT07343245Updated Jan 15, 2026

A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs

A Phase 1 interventional study of DW4421 and DW4421-N1 in Healthy Adult, sponsored by Daewon Pharmaceutical Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs

02

Conditions studied

  • Healthy Adult
03

In context

Lead sponsor

Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.
  • Subjects weighing between 50 kg and 90 kg with between 18 and 27 kg/m2 (inclusive) at screening visit.

Exclusion criteria

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cohort 1, A

    Drug: DW4421 · Drug: DW4421-N1

  • Experimental
    Cohort 1, B

    Drug: DW4421 · Drug: DW4421-N1

  • Experimental
    Cohort 2, C

    Drug: DW4421 · Drug: DW4421-N2

  • Experimental
    Cohort 2, D

    Drug: DW4421 · Drug: DW4421-N2

  • Experimental
    Cohort 3, E

    Drug: DW4421 · Drug: DW4421-N3

  • Experimental
    Cohort 3, F

    Drug: DW4421 · Drug: DW4421-N3

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Time frame: Baseline to Day 13 or Day 15

  2. AUCτ,ss

    Time frame: Baseline to Day 13 or Day 15

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 15, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Feb 22, 2026
CompletionEst.
Jun 17, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07343245
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Dec 1, 2025
Primary completion
Feb 22, 2026 (estimated)
Completion
Jun 17, 2026 (estimated)
Last update
Jan 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DW4421

Start the discussion